Vitality Watch

Dossier pubmed trial late 20-sep-2026
Large or late-phase randomized human trial

Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP.

Key claim: In a secondary analysis of the phase 3b STEP UP trial, semaglutide reduced adipose tissue and thigh muscle fat infiltration with modest skeletal muscle volume loss while preserving sit-to-stand physical function in adults with obesity.

Abstract

AIMS: To assess the effect of semaglutide on body composition and physical function. MATERIALS AND METHODS: The phase 3b STEP UP trial randomised adults with body mass index ≥ 30 kg/mto once-weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg or placebo for 72 weeks. This prespecified secondary analysis assessed changes in MRI body composition and physical function. RESULTS: Of 1407 participants, 55 with a valid baseline scan were included (semaglutide 7.2 mg, n = 43, 2.4 mg, n = 6 [pooled semaglutide group, n = 49]; placebo, n = 6). Estimated treatment differences (95% confidence intervals; p-values) for absolute changes in adipose/muscle compartment volumes for the pooled semaglutide versus placebo group, respectively, were: -11.1 L (-16.5 to -5.7; p < 0.0001) for adipose body tissue, -1.5 L (-2.9 to -0.1; p = 0.04) for visceral adipose tissue, -1.7 L (-4.0 to 0.7; p = 0.16) for lean body tissue, -1.1 L (-2.3 to 0.1; p = 0.07) for thigh skeletal muscle volume and -0.92%-points (-1.41 to -0.42; p = 0.001) for thigh muscle fat infiltration. Similar results were seen for relative changes in adipose/muscle compartment volumes. A sensitivity analysis for the semaglutide 7.2 mg group versus placebo showed similar results. A mean of 13 sit-to-stand repetitions in 30 s at baseline, and 15 repetitions at Week 72, was observed in the pooled semaglutide and placebo groups. CONCLUSIONS: Semaglutide plus lifestyle intervention was associated with reductions in adipose tissue volume, skeletal muscle volume and skeletal muscle fat infiltration, with a preserved number of sit-to-stand repetitions. Further research to assess the impact of weight loss on skeletal muscle composition and function should be explored in the future. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT05646706.

Why this matters

The GLP-1 muscle-loss concern is the single most persistent critique of anti-obesity medications as longevity tools, and STEP UP’s MRI substudy is one of the first phase 3b readouts to quantify muscle volume, fat infiltration, and a functional endpoint together. Showing modest muscle volume loss alongside reduced intramuscular fat and preserved sit-to-stand tightens what the muscle-quality picture actually looks like at high semaglutide doses — without answering whether the same holds in older or frailer users.

Source

Link

Briefing card

Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP.
Stage: trial late · pubmed · 20-sep-2026

If you are taking high-dose semaglutide for obesity, this trial found thigh muscle volume dropped modestly while muscle fat infiltration fell and sit-to-stand function held up over the study period.

In a secondary analysis of the phase 3b STEP UP trial, semaglutide reduced adipose tissue and thigh muscle fat infiltration with modest skeletal muscle volume loss while preserving sit-to-stand physical function in adults with obesity.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1111/dom.71323

build build 880 · 2bcef25 · 2026-11-18